Posted by Michael Wonder on 19 Sep 2023
Orchard Therapeutics announces acceptance of biologics license application for OTL-200 in MLD and receives priority review
18 September 2023 - PDUFA date set for 18 March 2024.
Orchard Therapeutics today announced the US FDA has accepted the filing of its biologics license application for OTL-200 in metachromatic leukodystrophy under priority review.
